RNASEH2B

Across TCGA pan-cancer cohorts, RNASEH2B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RNASEH2B data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNASEH2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNASEH2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where RNASEH2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.504	0.763	<.001	117	view →
LUAD	DFS	Median	All	0.741	0.506	.004	41	view →
PDAC	OS	Quartile	III,IV	0.198	0.847	.006	18	view →
CCRCC	DFS	Median	III,IV	0.760	0.960	.010	10	view →
UCEC	DFS	Median	II,III,IV	0.545	0.870	.043	4	view →
GBM	DFS	Quartile	All	0.504	0.231	.013	4	view →
LSCC	OS	Median	II,III,IV	1.000	0.889	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNASEH2B–HNSC (DFS)

Open the HNSC breakdown →